FAIRFIELD, NJ--(Marketwired - June 02, 2016) - StayinFront, the global leader of mobile cloud-based field force automation and CRM solutions, today announced that ADMA Biologics, a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, has selected StayinFront's CRM solutions as part of ADMA's ongoing commercialization activities.
ADMA looks forward to deploying the latest release of StayinFront TouchRx®, a SaaS-based mobile CRM tool with advanced targeted and call tracking to empower sales representatives to work more efficiently in the field. Integrated analytics, KPIs and updated customer data are expected to provide ADMA with critical information to analyze patterns, target leads and optimize sales territories.
"We believe StayinFront's solution will be a value added tool help our field team build and grow market awareness with a system that is intuitive and cost-effective," stated Alan Erck, VP Sales and National Accounts at ADMA Biologics. "StayinFront's strong track record of customer service and responsiveness, along with its deep knowledge of the life sciences industry and tools required for success, made selecting the TouchRx a logical choice for our CRM needs."
"StayinFront solutions will support ADMA's efforts to successfully launch new products and grow their business by enabling their field reps to do more, know more and achieve more," said Ken Arbadji, VP of North American Sales at StayinFront. "We are pleased to be partnering with ADMA Biologics and are committed to delivering world-class products and services that shorten their path to value."
About ADMA Biologics, Inc. (ADMA)
ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA's lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint, and a Biologics License Application (BLA) for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906 relating to certain aspects of its product candidate. For more information, please visit www.admabiologics.com.
About StayinFront
StayinFront is a leading global provider of mobile, cloud-based field force effectiveness and customer relationship management solutions for life sciences and consumer goods organizations. Companies of all sizes in over 50 countries use StayinFront software to streamline sales operations and reduce the complexity, time and expense associated with field efforts. StayinFront products provide companies with timely, accurate field data and insight, enabling field reps and management to do more, know more and sell more. Headquartered in Fairfield, NJ, USA, StayinFront has offices in Chicago, the United Kingdom, Turkey, Ireland, India, Australia, Singapore, New Zealand and China. For more details visit http://stayinfront.com
Contact Information:
STAYINFRONT CONTACT:
KEN ARBADJI
(973) 461-4800
EMAIL :